$ITOS
iTeos Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093302 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $35.00M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.11M $12.46M
YoY Change -3.87% -7.28%
% of Gross Profit
Research & Development $36.69M $36.71M
YoY Change 19.74% 25.78%
% of Gross Profit
Depreciation & Amortization $302.0K $310.0K
YoY Change 0.67% 37.78%
% of Gross Profit
Operating Expenses $48.80M $49.17M
YoY Change 12.75% 15.36%
Operating Profit -$48.80M -$14.17M
YoY Change 12.75% -66.76%
Interest Expense $8.010M $7.817M
YoY Change 0.13% -2.8%
% of Operating Profit
Other Income/Expense, Net -$3.130M $67.00K
YoY Change -505.97% -79.45%
Pretax Income -$43.12M -$4.867M
YoY Change 29.0% -85.28%
Income Tax $2.243M $2.261M
% Of Pretax Income
Net Earnings -$45.40M -$7.100M
YoY Change 40.99% -79.3%
Net Earnings / Revenue -20.29%
Basic Earnings Per Share -$1.05 -$0.18
Diluted Earnings Per Share -$1.05 -$0.18
COMMON SHARES
Basic Shares Outstanding 36.52M 36.12M
Diluted Shares Outstanding 43.14M 39.70M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $488.7M $571.3M
YoY Change -18.41% -4.67%
Cash & Equivalents $123.7M $251.1M
Short-Term Investments $365.0M $320.2M
Other Short-Term Assets $13.36M $13.00M
YoY Change -3.17% 11.69%
Inventory
Prepaid Expenses
Receivables $35.00M $35.00M
Other Receivables $7.803M $7.348M
Total Short-Term Assets $544.9M $626.6M
YoY Change -11.99% 1.96%
LONG-TERM ASSETS
Property, Plant & Equipment $5.372M $5.334M
YoY Change 61.32% 109.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $160.2M $107.8M
YoY Change 249.02% 37.8%
Other Assets $928.0K $788.0K
YoY Change 5.69% -2.96%
Total Long-Term Assets $178.2M $125.2M
YoY Change 204.54% 40.4%
TOTAL ASSETS
Total Short-Term Assets $544.9M $626.6M
Total Long-Term Assets $178.2M $125.2M
Total Assets $723.1M $751.8M
YoY Change 6.7% 6.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.154M $11.06M
YoY Change 109.24% 111.5%
Accrued Expenses $943.0K $15.43M
YoY Change -95.72% -27.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.81M $34.67M
YoY Change 30.44% 15.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $54.57M $53.31M
YoY Change 6.58% 6.2%
Total Long-Term Liabilities $54.57M $53.31M
YoY Change 6.58% 6.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.81M $34.67M
Total Long-Term Liabilities $54.57M $53.31M
Total Liabilities $91.39M $87.97M
YoY Change 15.12% 9.66%
SHAREHOLDERS EQUITY
Retained Earnings $33.90M $79.30M
YoY Change -78.16% -57.68%
Common Stock $37.00K $37.00K
YoY Change 2.78% 2.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $631.7M $663.9M
YoY Change
Total Liabilities & Shareholders Equity $723.1M $751.8M
YoY Change 6.7% 6.83%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$45.40M -$7.100M
YoY Change 40.99% -79.3%
Depreciation, Depletion And Amortization $302.0K $310.0K
YoY Change 0.67% 37.78%
Cash From Operating Activities -$37.35M -$33.93M
YoY Change 10.18% 14.83%
INVESTING ACTIVITIES
Capital Expenditures $94.00K $442.0K
YoY Change -89.56% -36.86%
Acquisitions
YoY Change
Other Investing Activities -$91.40M $16.76M
YoY Change -487.27% -19.42%
Cash From Investing Activities -$91.49M $16.32M
YoY Change -503.04% -18.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -442.0K 122.4M
YoY Change 56035.78%
NET CHANGE
Cash From Operating Activities -37.35M -33.93M
Cash From Investing Activities -91.49M 16.32M
Cash From Financing Activities -442.0K 122.4M
Net Change In Cash -129.3M 104.8M
YoY Change 1054.31% -1235.73%
FREE CASH FLOW
Cash From Operating Activities -$37.35M -$33.93M
Capital Expenditures $94.00K $442.0K
Free Cash Flow -$37.45M -$34.37M
YoY Change 7.6% 13.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001808865
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39401
dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
339
dei Local Phone Number
LocalPhoneNumber
217 0162
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ITOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36521845
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251098000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251177000
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
320709000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
320709000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
320158000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
280739000
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
393000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2024Q2 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
727000
CY2023Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
135000
CY2024Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
6228000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
6365000
CY2024Q2 itos Unbilled Milestone Receivable
UnbilledMilestoneReceivable
35000000
CY2023Q4 itos Unbilled Milestone Receivable
UnbilledMilestoneReceivable
0
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13001000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12236000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
626605000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
550652000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5334000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
108164000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
108164000
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
107846000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
100539000
CY2024Q2 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
5465000
CY2023Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
4508000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
303000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
274000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5500000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6036000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
788000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
883000
CY2024Q2 us-gaap Assets
Assets
751841000
CY2023Q4 us-gaap Assets
Assets
667588000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11055000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11293000
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
15431000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7058000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5299000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8562000
CY2024Q2 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
0
CY2023Q4 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
9787000
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
1604000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2063000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1277000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1251000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
34666000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40014000
CY2024Q2 itos Grants Repayable
GrantsRepayable
6028000
CY2023Q4 itos Grants Repayable
GrantsRepayable
6609000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4239000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4807000
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
43040000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40930000
CY2024Q2 us-gaap Liabilities
Liabilities
87973000
CY2023Q4 us-gaap Liabilities
Liabilities
92360000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36519945
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36519945
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35838080
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35838080
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
37000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
601102000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
463799000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16560000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13240000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
79289000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
124633000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
663868000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
751841000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
667588000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35000000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35000000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12595000
CY2024Q2 us-gaap Revenues
Revenues
35000000
CY2023Q2 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
35000000
us-gaap Revenues
Revenues
12595000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36709000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29186000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71238000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54885000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12457000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13435000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25160000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25385000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
49166000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
42621000
us-gaap Operating Expenses
OperatingExpenses
96398000
us-gaap Operating Expenses
OperatingExpenses
80270000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14166000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42621000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61398000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67675000
CY2024Q2 itos Grant Income
GrantIncome
522000
CY2023Q2 itos Grant Income
GrantIncome
799000
itos Grant Income
GrantIncome
1472000
itos Grant Income
GrantIncome
1534000
CY2024Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
893000
CY2023Q2 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
386000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
1696000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
729000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
7817000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
8042000
us-gaap Interest Income Other
InterestIncomeOther
15203000
us-gaap Interest Income Other
InterestIncomeOther
15893000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
67000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
326000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2158000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2099000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4867000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33068000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40869000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47420000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2261000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1232000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4475000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2431000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7128000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34300000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39699053
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35768952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37771084
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35742641
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39699053
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35768952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37771084
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35742641
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7128000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34300000
us-gaap Net Income Loss
NetIncomeLoss
-45344000
us-gaap Net Income Loss
NetIncomeLoss
-49851000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-151000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
104000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2416000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1902000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-72000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1722000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-906000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1620000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7351000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35918000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48666000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53373000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5807000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
578000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2006000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
102000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15551000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
652262000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6964000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
218000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
104000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1722000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34300000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
623526000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7263000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2265000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-832000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-38216000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
541200000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8062000
CY2024Q2 itos Stock Issued During Period Value Employee Stock Purchase Plan And Release Of Restricted Stock Units1
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndReleaseOfRestrictedStockUnits1
2383000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
119574000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-151000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-72000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7128000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
663868000
us-gaap Profit Loss
ProfitLoss
-45344000
us-gaap Profit Loss
ProfitLoss
-49851000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
614000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
447000
us-gaap Share Based Compensation
ShareBasedCompensation
15325000
us-gaap Share Based Compensation
ShareBasedCompensation
12771000
itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-5527000
itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-5386000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-5000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
0
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-397000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
584000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1705000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
729000
itos Refundable Income Taxes
RefundableIncomeTaxes
140000
itos Refundable Income Taxes
RefundableIncomeTaxes
-1839000
itos Increase Decrease In Milestone Receivable
IncreaseDecreaseInMilestoneReceivable
35000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1051000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-702000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-218000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2512000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5130000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
989000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-399000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1318000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12595000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-2110000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66327000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56101000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
245073000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
139037000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
193182000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
128265000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
819000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53278000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11591000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2404000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
796000
itos Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
119994000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
122398000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
796000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2843000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1659000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68555000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251451000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285038000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251401000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216483000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
2000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
20000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
235000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1059000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-906000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-1620000
itos Offering Costs Included Within Accounts Payable
OfferingCostsIncludedWithinAccountsPayable
277000
itos Offering Costs Included Within Accounts Payable
OfferingCostsIncludedWithinAccountsPayable
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2384000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4321000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7100000
us-gaap Net Income Loss
NetIncomeLoss
-45300000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
79300000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
433853000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
961000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
432984000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
360000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
325000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2024Q2 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
5000000
CY2024Q2 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
5000000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
325690000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
325138000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
108163000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
107846000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
433853000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
432984000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
281035000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
280739000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
100208000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
100539000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2024Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2800000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5600000
CY2023Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2500000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5400000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9857000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9078000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4523000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4382000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5334000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2024Q2 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
14413000
CY2023Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
6956000
CY2024Q2 itos Accrued Professional And Other Fees
AccruedProfessionalAndOtherFees
1018000
CY2023Q4 itos Accrued Professional And Other Fees
AccruedProfessionalAndOtherFees
102000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15431000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7058000
itos Upfront Payment Received
UpfrontPaymentReceived
625000000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
0
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
10500000
itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.30
CY2021 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.0012
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
777000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
3121000
itos Grant Income
GrantIncome
1472000
itos Grant Income
GrantIncome
1534000
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
393000
CY2023Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2024Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6628000
CY2023Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6813000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2024Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
120000
CY2024Q2 itos Offering Cost Incurred
OfferingCostIncurred
300000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
20000000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8062000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15325000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12771000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15300000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12800000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8270220
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.73
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2119270
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
396036
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
30.95
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
405559
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.26
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9587895
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29754000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5366265
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21573000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.7
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.61
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22729000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14868000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-42808000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36184000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
17862000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18200000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1939000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11236000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4867000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33068000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40869000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47420000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2261000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1232000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4475000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2431000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.464
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.037
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.109
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.051
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.464
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.109
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2024Q2 itos Liability For Accrual Of Additional Interest Expense
LiabilityForAccrualOfAdditionalInterestExpense
1000000
itos Liability For Accrual Of Additional Interest Expense
LiabilityForAccrualOfAdditionalInterestExpense
2100000
CY2024Q2 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
6000000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.037
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.051
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2024Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2024Q2 itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
400000
itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
800000
CY2023Q2 itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
300000
itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
600000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0474
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0475
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
73000
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
981000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
235000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1059000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
421000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
278000
us-gaap Operating Lease Payments
OperatingLeasePayments
768000
us-gaap Operating Lease Payments
OperatingLeasePayments
549000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
754000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1503000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1467000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
968000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
786000
CY2024Q2 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
580000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6058000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
542000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5516000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1277000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4239000
CY2024Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7128000
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-34300000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-45344000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-49851000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39699053
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35768952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37771084
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35742641
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39699053
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35768952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37771084
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35742641
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1884542
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2028359
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1705906
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1790788

Files In Submission

Name View Source Status
0000950170-24-093302-index-headers.html Edgar Link pending
0000950170-24-093302-index.html Edgar Link pending
0000950170-24-093302.txt Edgar Link pending
0000950170-24-093302-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
itos-20240630.htm Edgar Link pending
itos-20240630.xsd Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
itos-20240630_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable